MX2023008839A - Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide. - Google Patents
Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide.Info
- Publication number
- MX2023008839A MX2023008839A MX2023008839A MX2023008839A MX2023008839A MX 2023008839 A MX2023008839 A MX 2023008839A MX 2023008839 A MX2023008839 A MX 2023008839A MX 2023008839 A MX2023008839 A MX 2023008839A MX 2023008839 A MX2023008839 A MX 2023008839A
- Authority
- MX
- Mexico
- Prior art keywords
- linaclotide
- delayed release
- modified
- methods
- release formulations
- Prior art date
Links
- 230000003111 delayed effect Effects 0.000 title abstract 2
- KXGCNMMJRFDFNR-WDRJZQOASA-N linaclotide Chemical compound C([C@H](NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@H]3CSSC[C@H](N)C(=O)N[C@H](C(N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N2)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC3=O)C(=O)N[C@H](C(NCC(=O)N1)=O)[C@H](O)C)C(O)=O)C1=CC=C(O)C=C1 KXGCNMMJRFDFNR-WDRJZQOASA-N 0.000 title abstract 2
- 229960000812 linaclotide Drugs 0.000 title abstract 2
- 108010024409 linaclotide Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 208000002551 irritable bowel syndrome Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides methods for treating a patient with a disorder, such as a GI disorder or symptoms associated with a GI or non-GI disorder, by administering a therapeutically effective amount of a delayed release pharmaceutical composition comprising linaclotide.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437566P | 2016-12-21 | 2016-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008839A true MX2023008839A (en) | 2023-08-14 |
Family
ID=61022424
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007574A MX2019007574A (en) | 2016-12-21 | 2017-12-21 | Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide. |
| MX2023008839A MX2023008839A (en) | 2016-12-21 | 2019-06-21 | Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007574A MX2019007574A (en) | 2016-12-21 | 2017-12-21 | Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3558337A1 (en) |
| JP (2) | JP2020512292A (en) |
| CN (1) | CN110475564A (en) |
| AU (1) | AU2017379082A1 (en) |
| BR (1) | BR112019012689A2 (en) |
| CA (1) | CA3048195A1 (en) |
| EA (1) | EA201991531A1 (en) |
| MA (1) | MA47112A (en) |
| MX (2) | MX2019007574A (en) |
| WO (1) | WO2018119191A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022536494A (en) * | 2019-06-10 | 2022-08-17 | アイアンウッド ファーマシューティカルズ， インコーポレイテッド | Treatment of abdominal pain associated with diarrhea-type irritable bowel syndrome |
| MX2024006550A (en) * | 2021-11-29 | 2024-06-12 | Ironwood Pharmaceuticals Inc | Pharmaceutical compositions for the treatment of visceral pain. |
| WO2023196821A2 (en) * | 2022-04-04 | 2023-10-12 | Thomas Jefferson University | Targeting neuropod cell gucy2c to control visceral pain and appetite |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7371727B2 (en) | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| PT2328601T (en) | 2008-08-15 | 2020-04-30 | Ironwood Pharmaceuticals Inc | Linaclotide-containing formulations for oral administration |
| WO2011020054A1 (en) * | 2009-08-13 | 2011-02-17 | Ironwood Pharmaceuticals Inc. | Method for modulating the pharmacodynamic effect of orally administered guanylate cyclase receptor agonists |
| PL2536742T3 (en) | 2010-02-17 | 2017-11-30 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| EP2603232B1 (en) * | 2010-08-11 | 2019-09-25 | Ironwood Pharmaceuticals, Inc. | Stable formulations of linaclotide |
| PL2776055T3 (en) | 2011-08-17 | 2017-06-30 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| US20160015644A1 (en) * | 2013-01-15 | 2016-01-21 | Ironwood Pharmaceuticals, Inc. | Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant |
| UA119335C2 (en) * | 2013-12-11 | 2019-06-10 | Айронвуд Фармасьютикалз, Інк. | LINACLOTID COMPOSITIONS WITH DELAYED RELEASE |
| JP2018516937A (en) * | 2015-06-05 | 2018-06-28 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | Modified or targeted release formulation of linaclotide |
-
2017
- 2017-12-21 EA EA201991531A patent/EA201991531A1/en unknown
- 2017-12-21 CA CA3048195A patent/CA3048195A1/en active Pending
- 2017-12-21 MX MX2019007574A patent/MX2019007574A/en unknown
- 2017-12-21 BR BR112019012689-9A patent/BR112019012689A2/en unknown
- 2017-12-21 WO PCT/US2017/067814 patent/WO2018119191A1/en not_active Application Discontinuation
- 2017-12-21 AU AU2017379082A patent/AU2017379082A1/en not_active Abandoned
- 2017-12-21 CN CN201780087073.0A patent/CN110475564A/en active Pending
- 2017-12-21 EP EP17833050.2A patent/EP3558337A1/en active Pending
- 2017-12-21 MA MA047112A patent/MA47112A/en unknown
- 2017-12-21 JP JP2019533167A patent/JP2020512292A/en active Pending
-
2019
- 2019-06-21 MX MX2023008839A patent/MX2023008839A/en unknown
-
2022
- 2022-04-27 JP JP2022073214A patent/JP2022093472A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017379082A1 (en) | 2019-07-04 |
| EA201991531A1 (en) | 2019-11-29 |
| MA47112A (en) | 2019-10-30 |
| WO2018119191A9 (en) | 2018-10-18 |
| JP2022093472A (en) | 2022-06-23 |
| CA3048195A1 (en) | 2018-06-28 |
| WO2018119191A1 (en) | 2018-06-28 |
| CN110475564A (en) | 2019-11-19 |
| MX2019007574A (en) | 2019-09-04 |
| JP2020512292A (en) | 2020-04-23 |
| BR112019012689A2 (en) | 2019-11-19 |
| EP3558337A1 (en) | 2019-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004557B (en) | Modulatory polynucleotides | |
| PH12016501966B1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| MX2023010042A (en) | Modulatory polynucleotides. | |
| PH12018500016A1 (en) | Agents, uses and methods for the treatment of synucleinopathy | |
| MX2018005340A (en) | Proteolysis targeting chimera compounds and methods of preparing and using same. | |
| EA201890051A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| EA201891199A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| NZ724878A (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| EA201890048A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| EA201890047A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| EA201891200A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| GB2541571A (en) | Pharmaceutical compositions | |
| MX2018007704A (en) | Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant. | |
| PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| EP4382164A3 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
| PH12016501830A1 (en) | Inhibitors of c5a for the treatment of viral pneumonia | |
| PH12016501441A1 (en) | Chimeric alkaline phosphate-like proteins | |
| EA201791875A1 (en) | COMBINED COMPOSITION OF THESOPHENZINE AND BETA BLOCKER | |
| MX2023008839A (en) | Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide. | |
| MY194448A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
| PH12017501122A1 (en) | Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof | |
| PH12017501601A1 (en) | Use of isolated fractions of mastic gum for treating optic neuropathy | |
| MX2015009153A (en) | Use of alpha 7 nicotinic acetylcholine receptor agonists. | |
| MA40642A (en) | Novel peptide derivatives and uses thereof | |
| TN2017000517A1 (en) | MULTl-PEPTIDE COMPOSITION |